-- Second quarter revenue of $169 million, increased 25% over prior year, demonstrating successful integration and synergies from Flexion acquisition –
-- Strong topline performance delivers solid net income and significantly positive adjusted EBITDA--
-- Conference call today at 8:30 a.m. ET --
Pacira BioSciences Reports Second Quarter 2022 Financial Results
Provided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.
